Syncom Formulations (India) Limited

Syncom Formulations Holds 38th AGM on Sep 30, 2026; Dividend Declared

Syncom Formulations held its 38th AGM on Sep 30, 2026. The company declared a 10% dividend (₹0.10 per share) for FY26. Key appointments including Rahul Vijay Bankda as MD and Rinki Ankit Bankda as Whole-Time Director were confirmed. Remuneration for CFO Ankur Vijay Bankda was also approved.

Syncom Formulations Promoters Voluntarily Waive Final Dividend for FY26

Syncom Formulations' Promoters and Promoter Group voluntarily waived their entitlement to the final dividend for FY26. The proposed dividend was ₹0.10 per share. The waiver covers 47,53,47,599 shares, amounting to ₹4,75,34,759.90.

Syncom Formulations: Trading Window Closed Oct 1 for Q2 FY27 Results

Syncom Formulations will close its trading window from October 1, 2026, until 48 hours after announcing its Q2 FY27 unaudited financial results. This measure complies with SEBI insider trading regulations, restricting trading by insiders during the closure period.

Syncom Formulations Fixes Record Date for 10% Dividend on Sep 23; AGM on Sep 30

Syncom Formulations has set September 23, 2026, as the record date for a 10% dividend (₹0.10 per share) for FY2025-26, subject to AGM approval. The 38th AGM will be held on September 30, 2026, via video conference. Shareholders can waive their dividend entitlement by September 26, 2026.

Syncom Formulations announces 38th AGM, E-voting, and Record Date

Syncom Formulations (India) Limited has announced its 38th AGM, scheduled with remote e-voting from September 27 to September 29, 2026. The record date is September 23, 2026. Details were published in newspapers on September 8, 2026.

Syncom Formulations Announces 38th AGM on Sep 30, 2026, Shares FY26 Annual Report Link

Syncom Formulations will hold its 38th AGM on September 30, 2026, via video conference. The Annual Report for FY 2025-26 is available online for shareholders. Letters are being sent to those with un-registered email addresses providing access details.

Syncom Formulations Submits FY26 BRSR Report

Syncom Formulations (India) Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY2025-26. The report complies with SEBI LODR Regulations and will also be filed in XBRL format and made available on the company website.

Syncom Formulations Announces 38th AGM on September 30, 2026

Syncom Formulations (India) Limited will hold its 38th Annual General Meeting (AGM) on September 30, 2026. The meeting will be conducted via Video Conference. The registered office will be considered the official venue for the proceedings.

Syncom Formulations Announces 38th AGM, Book Closure, and E-Voting Details

Syncom Formulations (India) Limited announced its 38th AGM details, including remote e-voting and book closure, via newspaper publications. Separately, Visdem Technosys Limited (formerly Kundan Edifice Limited) scheduled its 16th AGM for September 30, 2026, via video conferencing, with remote e-voting available.

Syncom Formulations Announces Unaudited Financial Results for Q1 FY27

Syncom Formulations (India) Limited has announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Board of Directors on August 11, 2026. Newspaper advertisements detailing these results were published on August 12, 2026.

Syncom Formulations Announces Key Management Changes, Board Reshuffle

Syncom Formulations has announced multiple management changes. Shri K.S. Bankda resigned as Whole-time Director, Shri V.S. Bankda as MD, and Shri R.V. Bankda as CFO. Smt. R.A. Bankda is appointed Whole-time Director and Shri R.V. Bankda as MD, effective Aug 12, 2026, subject to shareholder approval. Shri A.V. Bankda redesignated as CFO.

Syncom Formulations Announces 38th AGM on Sept 30, 2026, with E-Voting Facility

Syncom Formulations will hold its 38th AGM on September 30, 2026. Members can e-vote from September 27-29, 2026. The cut-off date for voting entitlement is September 23, 2026. CDSL will provide the e-voting platform.

Syncom Formulations Appoints New Cost and Internal Auditors for FY27

Syncom Formulations appointed M/s M. Goyal & Co. as Cost Auditors and M/s Bansal & Agrawal as Internal Auditors for FY27. The appointments were approved by the Board on August 11, 2026, and are effective from August 12, 2026.

Syncom Formulations Q1 FY27 Standalone Revenue ₹124.66 Cr, Profit ₹24.59 Cr

Syncom Formulations reported Q1 FY27 standalone revenue of ₹124.66 crore and profit after tax of ₹24.59 crore. Consolidated revenue was ₹133.36 crore, with profit after tax at ₹24.85 crore. The results were approved by the Board on August 11, 2026.

Syncom Formulations Fixes Record Date for 10% Dividend, Schedules 38th AGM for Sep 30

Syncom Formulations has set September 23, 2026, as the record date for a 10% dividend for FY26. The 38th AGM, where the dividend requires approval, is scheduled for September 30, 2026, conducted via VC/OAVM. Shareholders can waive dividends by September 26, 2026.

Syncom Formulations Fixes Record Date for 10% Dividend, AGM on Sep 30

Syncom Formulations has fixed September 23, 2026, as the record date for a 10% dividend (Rs. 0.10/share) for FY26. The 38th AGM will be held on September 30, 2026, via VC/OAVM for dividend approval. Shareholders can waive dividends by September 26, 2026.

Syncom Formulations Board Approves Q1 FY27 Results, Dividend, and Key Management Changes

Syncom Formulations' Board approved Q1 FY27 unaudited results and recommended a final dividend of ₹0.10 per share. Key management changes include resignations of MD, Whole-time Director, and CFO, and appointments of new MD, Whole-time Director, and CFO. The 38th AGM is scheduled for September 30, 2026.

Syncom Formulations MD, Vijay Shankarlal Bankda, Resigns Effective August 11, 2026

Mr. Vijay Shankarlal Bankda has resigned as Managing Director of Syncom Formulations (India) Limited. His resignation is effective August 11, 2026. The company received the resignation on August 8, 2026. This disclosure follows SEBI regulations.

Syncom Formulations CFO Rahul Vijay Bankda Resigns; Effective August 11, 2026

Syncom Formulations' CFO, Mr. Rahul Vijay Bankda, has resigned. His resignation is effective August 11, 2026. The company received his resignation letter on August 8, 2026, and has filed the necessary disclosures.

Syncom Formulations Announces Resignation of Whole-Time Director Kedarmal Bankda

Mr. Kedarmal Shankarlal Bankda has resigned as Whole-Time Director of Syncom Formulations (India) Limited. His resignation is effective August 11, 2026. The company received the resignation letter on August 8, 2026.

Syncom Formulations Files SEBI Compliance Certificate for Q1 FY27

Syncom Formulations (India) Limited submitted a compliance certificate for Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter ended June 30, 2026, and was provided by the Registrar and Share Transfer Agent, Ankit Consultancy Pvt. Ltd.

Syncom Formulations Publishes Extract of Audited Financial Results for Quarter/Year Ended 31 Mar 2026

Syncom Formulations released a press clipping on 23rd May 2026, concerning audited financial results for the quarter and year ended 31st March 2026. The Audit Committee and Board of Directors approved the results on 22nd May 2026. The advertisement was published in the "Business Standard" Journal.

Syncom Formulations Reports FY26 Audited Results: Standalone Profit at ₹2457.42 Lakhs

Syncom Formulations reported FY26 audited results. Standalone profit after tax was ₹7,600.80 lakhs (year-ended) and ₹2,457.42 lakhs (Q4). Consolidated profit after tax was ₹7,643.80 lakhs (year-ended) and ₹2,517.44 lakhs (Q4). The company updated its EPS calculation methodology.

Syncom Formulations Files Compliance Certificate for Q4 FY26

Syncom Formulations (India) Limited submitted a compliance certificate for Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate covers the quarter ended March 31, 2026. It confirms the processing of dematerialized securities and updates to the register of members.

Syncom Formulations Promoters Submit Yearly Disclosure Under SEBI (SAST) Regulations 2011

Syncom Formulations' Promoters, Shri Kedarmal Shankarlal Bankda and Shri Vijay Shankarlal Bankda, have submitted their yearly disclosure for the financial year ended March 31, 2026, as per SEBI (SAST) Regulations, 2011. The disclosure was made to the company's Audit Committee and the stock exchanges.

Syncom Formulations: Trading Window Closed from April 1 for Financial Results

Syncom Formulations will close its trading window from April 1, 2026, until 48 hours after announcing audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. This is in compliance with SEBI insider trading regulations.

Syncom Formulations (India) Limited Files Newspaper Clipping for Un-Audited Financial Results

Syncom Formulations (India) Limited announced its un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The results were approved by the Audit Committee and Board of Directors on February 12, 2026, and published in newspapers on February 13, 2026.

Syncom Formulations Q3FY26 Standalone Profit Rises 45% to ₹18.86 Crore

Syncom Formulations reported strong Q3FY26 results. Standalone profit after tax surged to ₹18.86 crore from ₹12.79 crore year-on-year. Consolidated profit after tax increased to ₹18.91 crore from ₹13.00 crore. Revenue from operations for the quarter was ₹114.59 crore (standalone) and ₹115.44 crore (consolidated).

Syncom Formulations Files SEBI Compliance Certificate for Q3 FY26

Syncom Formulations (India) Limited submitted a compliance certificate for Q3 FY26 (ended December 31, 2025) as per SEBI (Depositories and Participants) Regulations, 2018. The certificate from registrar and share transfer agent confirms proper handling of dematerialization and cancellation of security certificates.

Syncom Formulations Receives Demand Notice of ₹1.41 Crore for Ineligible ITC and Penalty

Syncom Formulations received a revised demand and penalty notice from the GST Department for ₹1.41 crore. This includes ₹70.89 lakh as ineligible Input Tax Credit and ₹70.89 lakh as penalty, totaling ₹1.41 crore. The company intends to appeal this demand.

Syncom Formulations: Trading Window Closed Jan 1, 2026 for Q3 FY26 Results

Syncom Formulations (India) Limited will close its trading window from January 1, 2026. This closure is to facilitate the announcement of Unaudited Standalone & Consolidated Financial Results for the quarter and nine months ending December 31, 2025. The window will reopen 48 hours after the results declaration.

Syncom Formulations acquires commercial property for ₹51.70 crore

Syncom Formulations acquired a commercial property, paying ₹51.70 crore to HDFC Bank Ltd for the entire 3rd Floor, Trade Star, Andheri -Kurla Road, Andheri (E), Mumbai.

Syncom Formulations: Newspaper Publication on Unaudited Financial Results

Syncom Formulations published an extract of unaudited financial results for the quarter/half year ended September 30, 2025, following board approval on November 12, 2025, in Business Standard.

Syncom Formulations Reports Strong Q2 & H1 FY26 Financial Results with Significant Growth

Syncom Formulations reported robust Q2 and H1 FY26 results. Standalone and consolidated revenues and profits significantly increased year-over-year, driven by strong performance in the Pharmaceuticals segment.

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Syncom Formulations submitted compliance certificate under SEBI regulations for quarter ended September 30, 2025.

Syncom Formulations Appoints D.K. Jain & Co. as Secretarial Auditor

Syncom Formulations Approves Alterations to AOA and MOA

Syncom Formulations Appoints Ankit Kedarmal Bankda as Chairman & Whole Time Director

Syncom Formulations: AGM Results - All Resolutions Passed on 29 Sep 2025

Syncom Formulations announces dispatch of AGM notice and e-voting details.

Syncom Formulations to Hold 37th AGM on September 29, 2025 via VC

Syncom Formulations Launches "Saksham Niveshak" Campaign for Unclaimed Dividends

Syncom Formulations announces 37th AGM date, e-voting cutoff, and book closure

Newspaper Publication: Unaudited Financial Results for Quarter Ended 30 Jun 2025

Syncom Formulations Reports Strong Q1 FY2026 YoY Growth in Revenue and Profit